Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
Overseen ByLi Zhang, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Akeso
No Placebo Group
Trial Summary
What is the purpose of this trial?A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
Eligibility Criteria
Participant Groups
1Treatment groups
Experimental Treatment
Group I: AK104Experimental Treatment1 Intervention
AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Loading ...
Who is running the clinical trial?
AkesoLead Sponsor
Akeso Pharmaceuticals, Inc.Collaborator